Watertown, MA– Landmark Bio, a rising force in the development and manufacturing of advanced therapies, has been acquired by Artis BioSolutions, a newly established company focused on optimizing the discovery, process development, and manufacturing of genetic medicines. This acquisition marks a significant step for Landmark Bio, enabling the company to scale its capabilities and accelerate the delivery of breakthrough therapies.
The acquisition will allow Landmark Bio to further its mission of translating pioneering research into life-changing treatments while expanding its infrastructure to meet the growing demand for advanced therapy development. Landmark Bio’s current operations will remain independent, leveraging its strong presence within Massachusetts’ life sciences ecosystem.
Ran Zheng, CEO of Landmark Bio, expressed enthusiasm about the partnership, emphasizing the shared vision between the company’s founders and Artis BioSolutions. “Landmark Bio was born from a bold vision to remove barriers in advanced therapy manufacturing and accelerate the development of life-changing medicines. In just a few short years, we’ve built a world-class team and capabilities. This partnership with Artis BioSolutions marks an exciting new chapter in our mission to bring groundbreaking therapies to more patients,” said Zheng.
Founded in 2021, Landmark Bio has built a robust platform aimed at addressing persistent bottlenecks in advanced therapy development. The company has partnered with academic institutions, biotech companies, and global biopharma firms, becoming a vital player in the life sciences innovation ecosystem. The acquisition will enable Landmark Bio to enhance its service offerings, spanning preclinical development through to commercialization, with expanded capabilities in process development, GMP manufacturing, analytical services, QC testing, and regulatory consulting.
John Shaw, Vice Provost for Research at Harvard University and Chair of Landmark Bio’s Board of Directors, praised the acquisition. “Landmark Bio plays an important role in advancing new therapies, and we believe this transition will solidify its position as a cornerstone of the advanced therapy ecosystem.”
Brian Neel, CEO of Artis BioSolutions, expressed confidence in the future of the partnership, noting the strong foundation already established by Landmark Bio. “Ran and his team have built an organization founded on scientific excellence, operational precision, and a commitment to collaboration. We are thrilled to join forces with Landmark Bio and look forward to driving innovation together—expanding access, accelerating progress, and helping our partners deliver life-changing medicines to patients more efficiently.”
As part of the deal, Landmark Bio will continue to operate as a separate entity under the Artis umbrella, maintaining its focus on translational research, process development, and manufacturing for clinical and commercial cell and gene therapy products. The acquisition was supported by initial funding from Oak HC/FT and represents a major step toward providing high-quality development and manufacturing capabilities to the broader advanced therapy sector.
Headquartered in Watertown, MA, Landmark Bio will continue to operate from its state-of-the-art facilities and maintain its current team as it prepares to scale its operations and broaden its impact in the rapidly evolving biopharmaceutical landscape.
